Mechanism of action<unk>  works by binding to a site on the bacterial 30S and 50S ribosome, preventing formation of the 70S complex. As a result, mRNA cannot be translated into protein, and cell death ensues.<unk>  also binds to RNA-aptamers, artificially created molecules to bind to certain targets. However, there seems to be no indication that<unk>  binds to natural RNAs or other nucleic acids. The effect of<unk>  can be inhibited by metabolites of the Krebs (TCA) cycle, such as glyoxylate. These metabolites protect against<unk>  lethality by diverting carbon flux away from the TCA cycle, collapsing cellular respiration, and thereby inhibiting<unk>  uptake and thus lethality. Pharmacokinetics<unk>  is not absorbed in the gut. When given as infusion, it is distributed in the extracellular fluid. It can accumulate in the kidney's tubular cells and in the lymph of the inner ear. Only low concentrations reach the central nervous system and breast milk.<unk>  passes the placenta: in the fetus, 20% of the mother's concentrations have been measured. The substance is neither bound to plasma proteins, nor is it metabolized. It is excreted in unchanged form via the kidneys with a biological half-life of about 2 to 3 hours. Elimination from deep compartments such as the renal cortex follows after 8 to 12 hours. In newborns the half-life is 4.6 hours on average; in those with a low birth weight it is as long as 8.7 hours on average. People with reduced kidney function also have a longer half-life for<unk> , while in those with severe burns it can be shorter.
Tobramycin
Meropenem
Imipenem/cilastatin/relebactam
Amikacin
Teicoplanin
Resistin
Moxifloxacin
Telithromycin